Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
EYENOVIA, INC. (EYEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 8-K Investor presentation
Docs: "Eyenovia Acquires U.S. Commercial Rights to APP13007 from Formosa Pharmaceuticals",
"2024 2025 2026 2027 2028 2029"
08/10/2023 8-K Quarterly results
Docs: "Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update"
05/11/2023 8-K Investor presentation, Quarterly results
Docs: "Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update",
"Forward-looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Ther..."
05/08/2023 8-K Quarterly results
02/28/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of"
01/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eyenovia, Inc. Updated Corporate Presentation dated February 2023"
12/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation"
12/08/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President"
11/29/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund"
11/10/2022 8-K Quarterly results
Docs: "Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update"
11/07/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
10/20/2022 8-K Quarterly results
09/30/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
07/27/2022 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member"
07/07/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eyenovia, Inc. Corporate Update Presentation dated April 2022"
03/28/2022 8-K Quarterly results
Docs: "Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results"
03/09/2022 8-K/A Quarterly results
03/07/2022 8-K Quarterly results
02/08/2022 8-K Quarterly results
02/07/2022 8-K Quarterly results
12/14/2021 8-K Quarterly results
12/06/2021 8-K Quarterly results
12/03/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Eyenovia Reports Third Quarter 2021 Financial Results"
11/05/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia"
10/25/2021 8-K Investor presentation
Docs: "Eyenovia Announces Reclassification of MydCombi as Drug-Device Combination Product by FDA",
"2020 1 IMS, 2015 2"
09/15/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy